9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 840Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Primary Purpose: TreatmentStudy ID Numbers: BTS-MRC-MS01|CDR0000347461|ISRCTN54469112|EU-20349Study First Received: January 9, 2004Last Updated: August 6, 2013Estimated Primary Completion Date: nullPrimary Outcome Measures:Overall survival|Palliation of chest pain, breathlessness, malaise (e.g., feeling weak, tiredness, anorexia), and sweating attacks|Performance status as measured by WHO grade|Analgesic usage|Toxicity as measured by the NCIC CTC|Quality of life as assessed by the European Organization for Research and Treatment of Cancer|Tumor response as measured by the RECIST criteria|Progression-free survival as measured by CT scanSponsors and Collaborators:Medical Research Council|National Cancer Institute (NCI)Result...

Continue reading

Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 6Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CDR0000066157|P30CA006927|FCCC-96087|NCI-G98-1401Study First Received: November 1, 1999Last Updated: April 16, 2013Estimated Primary Completion Date: December 1999Primary Outcome Measures:Sponsors and Collaborators:Fox Chase Cancer Center|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00003263...

Continue reading

SU5416 in Treating Patients With Malignant Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 45Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NCI-2012-02351|UCCRC-10409|UCCRC-NCI-44|NCI-44|CDR0000068023Study First Received: July 5, 2000Last Updated: May 31, 2013Estimated Primary Completion Date: February 2007Primary Outcome Measures:Sponsors and Collaborators:National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00006014...

Continue reading

Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery

ConditionMalignant MesotheliomaEstimated Enrollment: 60Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Primary Purpose: TreatmentStudy ID Numbers: CDR0000564058|COL-ALIMESO|INCA-RECF0441|COL-2006-04Study First Received: October 5, 2007Last Updated: May 14, 2011Estimated Primary Completion Date: May 2011Primary Outcome Measures:Individual dosage-adapted protocol|Relationship between pharmacokinetic and pharmacodynamic parameters|Pharmacokinetics|Pharmacogenetic variations (MTHFR, TS, GSTpi, ERCC1, XPD)Sponsors and Collaborators:Centre Oscar Lambret|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00541073...

Continue reading

Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery

ConditionMalignant MesotheliomaEstimated Enrollment: nullAge Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Primary Purpose: TreatmentStudy ID Numbers: 99-085|CDR0000067791|CWRU-LILY-1599|LILLY-H3E-MC-JMCH(a)|NCI-G00-1767Study First Received: May 2, 2000Last Updated: June 17, 2013Estimated Primary Completion Date: November 2000Primary Outcome Measures:Sponsors and Collaborators:Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00005636...

Continue reading

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

ConditionPleural Malignant MesotheliomaEstimated Enrollment: 14Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Primary Purpose: TreatmentStudy ID Numbers: UPCC 03510Study First Received: April 27, 2010Last Updated: December 14, 2015Estimated Primary Completion Date: October 2012Primary Outcome Measures:3-month PFS rate|Estimate the distribution of progression-free and over survivalSponsors and Collaborators:Abramson Cancer Center of the University of PennsylvaniaResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01112293...

Continue reading

Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 78Age Group: 18 Years to 85 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 86/12/02Study First Received: November 10, 2010Last Updated: November 17, 2010Estimated Primary Completion Date: June 2010Primary Outcome Measures:Response rate|Safety and tolerabilitySponsors and Collaborators:Institute of Oncology Ljubljana|Ministry of Higher Education, Science and Technology, SolveniaResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01243632...

Continue reading

Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 40Age Group: 18 Years to 85 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: MPM phase II Carbo/VNBStudy First Received: January 3, 2006Last Updated: September 17, 2009Estimated Primary Completion Date: September 2009Primary Outcome Measures:Response|Survival|FeasibilitySponsors and Collaborators:Rigshospitalet, DenmarkResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00272558...

Continue reading

Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma

ConditionMalignant (Pleural) MesotheliomaEstimated Enrollment: 10Age Group: Child, Adult, SeniorGender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NL24050.000.08Study First Received: June 1, 2010Last Updated: February 26, 2014Estimated Primary Completion Date: October 2011Primary Outcome Measures:number of cytotoxic T cells and regulatory T cells in the blood of patients|safety and toxicitySponsors and Collaborators:Erasmus Medical CenterResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01241682...

Continue reading

Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed

ConditionMalignant MesotheliomaEstimated Enrollment: 25Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Primary Purpose: TreatmentStudy ID Numbers: EORTC-08992Study First Received: January 28, 2000Last Updated: July 17, 2012Estimated Primary Completion Date: June 2001Primary Outcome Measures:Sponsors and Collaborators:European Organisation for Research and Treatment of Cancer - EORTCResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00004254...

Continue reading